CN102666543B - 二酰基甘油酰基转移酶抑制剂 - Google Patents

二酰基甘油酰基转移酶抑制剂 Download PDF

Info

Publication number
CN102666543B
CN102666543B CN201080055334.9A CN201080055334A CN102666543B CN 102666543 B CN102666543 B CN 102666543B CN 201080055334 A CN201080055334 A CN 201080055334A CN 102666543 B CN102666543 B CN 102666543B
Authority
CN
China
Prior art keywords
benzazepine
dihydro
imidazo
hours
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080055334.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102666543A (zh
Inventor
M·B·阿诺尔德
T·J·博尚
E·J·加纳达
E·J·亨布雷
J·陆
J·R·里佐
J·M·绍斯
Q·史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102666543A publication Critical patent/CN102666543A/zh
Application granted granted Critical
Publication of CN102666543B publication Critical patent/CN102666543B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201080055334.9A 2009-12-10 2010-12-07 二酰基甘油酰基转移酶抑制剂 Expired - Fee Related CN102666543B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28531709P 2009-12-10 2009-12-10
US61/285,317 2009-12-10
PCT/US2010/059158 WO2011071840A1 (en) 2009-12-10 2010-12-07 Inhibitors of diacylglycerol acyltransferase

Publications (2)

Publication Number Publication Date
CN102666543A CN102666543A (zh) 2012-09-12
CN102666543B true CN102666543B (zh) 2014-12-24

Family

ID=43569741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080055334.9A Expired - Fee Related CN102666543B (zh) 2009-12-10 2010-12-07 二酰基甘油酰基转移酶抑制剂

Country Status (14)

Country Link
US (1) US8299061B2 (cg-RX-API-DMAC7.html)
EP (1) EP2509981B1 (cg-RX-API-DMAC7.html)
JP (1) JP5631411B2 (cg-RX-API-DMAC7.html)
KR (1) KR101395428B1 (cg-RX-API-DMAC7.html)
CN (1) CN102666543B (cg-RX-API-DMAC7.html)
AR (1) AR079170A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010328410B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012013918A2 (cg-RX-API-DMAC7.html)
CA (1) CA2783684C (cg-RX-API-DMAC7.html)
EA (1) EA020128B1 (cg-RX-API-DMAC7.html)
ES (1) ES2509922T3 (cg-RX-API-DMAC7.html)
MX (1) MX2012006646A (cg-RX-API-DMAC7.html)
TW (1) TWI392680B (cg-RX-API-DMAC7.html)
WO (1) WO2011071840A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
NZ705225A (en) 2010-07-16 2016-11-25 Abbvie Bahamas Ltd Process for preparing antiviral compounds
WO2015120610A1 (en) * 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound
CN105153195B (zh) * 2015-09-01 2017-09-26 汤文建 一种三环吡唑[1,5‑d][1,4]苯并氧氮杂卓酮衍生物及其制备方法与用途
CA3142360C (en) * 2019-05-31 2023-11-14 Medshine Discovery Inc. Bicyclic compound as rip-1 kinase inhibitor and application thereof
TWI824259B (zh) * 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014671A1 (en) * 1993-11-22 1995-06-01 Merck & Co., Inc. 3-acylaminobenzazepines
WO2006020959A2 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
CN101171231A (zh) * 2005-05-10 2008-04-30 霍夫曼-拉罗奇有限公司 二酰基甘油酰基转移酶抑制剂
WO2010056496A1 (en) * 2008-11-14 2010-05-20 Merck Sharp & Dohme Corp. Azepinone derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847248A (en) * 1986-12-23 1989-07-11 Merck & Co., Inc. 1,4-Benzodiazepines with 5- and 6-membered heterocyclic rings and their use as cholecystokinins and gastrin antagonists
US4735941A (en) * 1986-12-23 1988-04-05 Merck & Co., Inc. 1,4-benzodiazepines with 5- and 6-membered heterocyclic rings, useful as gastrointestinal and CNS agents
EP0272866A1 (en) 1986-12-23 1988-06-29 Merck & Co. Inc. 1,4-Benzodiazepines with 5-membered heterocyclic rings
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
EP0523846A3 (en) 1991-06-14 1993-03-17 Merck & Co. Inc. 1,4-benzodiazepines with 5-membered heterocyclic rings
US5679672A (en) * 1993-11-22 1997-10-21 Merck & Co., Inc. Benzodiazepines
US5439906A (en) * 1993-11-22 1995-08-08 Merck & Co., Inc. Antiarrhythmic benzodiazepines
US5834464A (en) * 1994-11-18 1998-11-10 Merck & Co., Inc. Imidazolinobenzodiazepines
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
GB0012671D0 (en) * 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
CA2615463A1 (en) 2005-07-29 2007-02-08 Merck & Co., Inc. Heterocyclic benzodiazepine cgrp receptor antagonists
US7569590B2 (en) * 2006-09-19 2009-08-04 Bristol-Myers Squibb Company Use of thianecarboxamides as dgat inhibitors
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
WO2009126861A2 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolopyridine compounds useful as dgat1 inhibitors
US20110319396A1 (en) 2009-01-23 2011-12-29 Msd K.K. Benzodiazepin-2-on derivatives
AU2010216632A1 (en) 2009-02-17 2011-08-04 Msd K.K. 1,4-benzodiazepin-2-on derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014671A1 (en) * 1993-11-22 1995-06-01 Merck & Co., Inc. 3-acylaminobenzazepines
WO2006020959A2 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
CN101171231A (zh) * 2005-05-10 2008-04-30 霍夫曼-拉罗奇有限公司 二酰基甘油酰基转移酶抑制剂
WO2010056496A1 (en) * 2008-11-14 2010-05-20 Merck Sharp & Dohme Corp. Azepinone derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor;Gang Zhao,等;《J. Med. Chem.》;20080110;第51卷(第3期);第380-383页,参见全文 *

Also Published As

Publication number Publication date
AU2010328410A1 (en) 2012-07-26
JP2013513607A (ja) 2013-04-22
EA020128B1 (ru) 2014-08-29
AR079170A1 (es) 2011-12-28
CN102666543A (zh) 2012-09-12
MX2012006646A (es) 2012-06-25
US20110144091A1 (en) 2011-06-16
KR101395428B1 (ko) 2014-05-14
CA2783684A1 (en) 2011-06-16
AU2010328410B2 (en) 2014-02-06
BR112012013918A2 (pt) 2016-04-26
TWI392680B (zh) 2013-04-11
TW201130844A (en) 2011-09-16
EP2509981A1 (en) 2012-10-17
EA201200868A1 (ru) 2012-12-28
WO2011071840A1 (en) 2011-06-16
ES2509922T3 (es) 2014-10-20
KR20120099457A (ko) 2012-09-10
US8299061B2 (en) 2012-10-30
EP2509981B1 (en) 2014-08-06
CA2783684C (en) 2014-02-25
JP5631411B2 (ja) 2014-11-26

Similar Documents

Publication Publication Date Title
JP5642963B2 (ja) ピリジノニルpdk1阻害剤
CN102666543A (zh) 二酰基甘油酰基转移酶抑制剂
CN111225915B (zh) 作为pad抑制剂的咪唑并吡啶化合物
CN104684915B (zh) 新型双环衍生物
TWI417092B (zh) Iap抑制劑
CN100448874C (zh) N-芳酰基环胺
EP4031552B1 (en) Azole-fused pyridazin-3(2h)-one derivatives
TWI465444B (zh) 抗病毒化合物
CN112074505B (zh) 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
CN109311865B (zh) 抗乙肝病毒的吡唑-噁唑烷酮类化合物
MX2011005221A (es) Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b.
CN111434662B (zh) 卤代烯丙基胺类化合物及其应用
JP2020524148A (ja) 置換5−シアノインドール化合物及びその使用
CN104024232A (zh) 新吡嗪衍生物
CN105102450A (zh) 作为PERK抑制剂的新颖的N-(2,3-二氢-1H-吡咯并[2,3-b]吡啶-5-基)-4-喹唑啉胺和N-(2,3-二氢-1H-吲哚-5-基)-4-喹唑啉胺衍生物
JP2022510351A (ja) バニン阻害剤としての複素芳香族化合物
CN105254628B (zh) 吡唑并吡啶类抗肿瘤化合物及其制备方法和应用
CN101528735A (zh) 新的芴衍生物,包含它们的组合物和作为伴侣蛋白hsp90抑制剂的用途
CN105503863A (zh) 新型抗肿瘤化合物
WO2009094866A1 (en) Dicycloazaalkane derivates, preparation processes and medical uses thereof
WO2018158210A1 (en) Pyridyl derivatives as bromodomain inhibitors
HK40118929A (en) N3-substituted uracil compounds as trpa1 inhibitors
HK1253870A1 (en) Inhibitors of plasma kallikrein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141224

Termination date: 20151207

EXPY Termination of patent right or utility model